Ted Moon
Managing Partner (US)
Claimed by owner
RMGP Biopharma Investment Fund
www.calcalistech.com
Apr 9, 2019
RM Global Raises Additional $34 Million for Israel-Based Biopharma Investment Fund
en.globes.co.il
May 18, 2017
RM Global to invest $30m in FutuRx biotech startups
About
The RMGP Biopharma Investment Fund represents an opportunity to invest alongside industry leaders in innovative early-stage biotherapeutics through a dedicated platform. RMGP and its partners identified innovative early-stage biopharmaceutical assets as a highly attractive investment opportunity.
The fund invests in early-stage biopharmaceutical solutions alongside industry leaders such as OrbiMed, J&J, and Takeda. The fund is dedicated to FutuRx's portfolio of first-in-class and best-in-class assets, and it invests exclusively in companies operating in Israel's FutuRx incubator. Based on RM Global's core investment banking capabilities, the fund will provide its portfolio companies with strategic and business development support to maximize potential return.
The fund invests in early-stage biopharmaceutical solutions alongside industry leaders such as OrbiMed, J&J, and Takeda. The fund is dedicated to FutuRx's portfolio of first-in-class and best-in-class assets, and it invests exclusively in companies operating in Israel's FutuRx incubator. Based on RM Global's core investment banking capabilities, the fund will provide its portfolio companies with strategic and business development support to maximize potential return.
News
(2)www.calcalistech.com
Apr 9, 2019
RM Global Raises Additional $34 Million for Israel-Based Biopharma Investment Fund
en.globes.co.il
May 18, 2017
RM Global to invest $30m in FutuRx biotech startups
The Team
(7)
TM
BR
Bruce Roberts
Managing Partner (US)
YB
Yaron Breski
General Partner
AK
Assaf Keret
General Partner
LV
Lidia Verra
VP Finance
YC
Yulia Cladco
Associate
LB
Leeat Bar-Eyal
Associate
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Exits
Reverse Merger
Nov 2019
Stock Exchange
NYSE
Acquired Company
Chardan Healthcare Acquisition Corp
Funds
(1)
Fund 1
Apr 2019
$64M
Israeli Portfolio
( 22 )
Company Name
Description
Founded
Business Model
Employees
Funding Stage
Raised
Protekt Therapeutics
PKR Inhibition for Treating Neurodegenerative Diseases
2014
B2B
1-10
Seed
$2.25M
Skip Therapeutics
RNA-based Therapies for Genetic Disorders
2021
B2B
1-10
Seed
undisclosed
TNIK Therapeutics
Small Molecule Inhibitors of TNIK
2018
B2B
1-10
Seed
undisclosed
Pi Therapeutics
Inhibitors for Cancer Treatment
2015
B2B
1-10
B
$19.7M
Ramino-Bio
Treatment of Cardiometabolic Diseases Using Enhanced Branched-chain Amino Acids
2018
B2B
1-10
Seed
undisclosed
Selene Therapeutics
Epilepsy Therapy
2020
B2B
1-10
Seed
undisclosed
Bsense Bio Therapeutics
Neuropathic Pain Treatment
2018
B2B
1-10
Seed
$2.7M
Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
2016
B2B
1-10
A
$20M
Epeius Pharma
Delivery of Therapeutic Proteins into the Central Nervous System
2019
B2B
1-10
Seed
$814K
Nevrox
Therapeutic Small Molecule Inhibitor for Treating Neurodegenerative Disorders
2019
B2B
1-10
Seed
undisclosed
Circuit-Bio
Platform of Logical Gene Circuits for Cancer Immunotherapy
2020
B2B
1-10
Seed
undisclosed
BiomX
Microbiome Therapies for Chronic Diseases
2015
B2B
51-200
Public
$81.5M
A2i Therapeutics
Novel Small-molecule Immuno-oncology Agents
2020
B2B
1-10
Seed
undisclosed
HepaRx
Small Molecule Cancer Drugs
2014
B2B
1-10
Pre-Funding
undisclosed
Pink Biopharma
Monoclonal Antibody Therapy for Blood and Bone Cancer
2018
B2B
1-10
Seed
$3M
Symbol Therapeutics
Modified Protein for Treatment of Autoimmune Diseases
2021
B2B
1-10
Seed
$3M
Glixogen Therapeutics
Treatment for Enhancing Remyelination in Neurodegenerative Disorders
2018
B2B
1-10
Seed
undisclosed
ImmPACT Bio
CAR-T Cell Therapies for Treating Cancer
2017
B2B
51-200
B
$129M
XL Therapeutics
Treatment of Conditions Caused by Deficiencies in WAS Protein Expression
2016
B2B
1-10
Pre-Funding
undisclosed
MabTrix
Therapeutic Monoclonal Antibody for Bowel Disease
2015
B2B
1-10
Seed
undisclosed
Moya Bio
Tumor Immune Conditioning Agents
2017
B2B
1-10
Seed
undisclosed
JAMM Therapeutics
Systemic Lupus Erythematosus Treatment
2019
B2B
1-10
Seed
undisclosed
Investments
(24)
Date
Name
Description
Round Type
Lead Investor
Follow on
Amount
Sep 2022
Symbol Therapeutics
Modified Protein for Treatment of Autoimmune Diseases
Seed
Undisclosed
Jan 2022
ImmPACT Bio
CAR-T Cell Therapies for Treating Cancer
B Round
Undisclosed
May 2021
Skip Therapeutics
RNA-based Therapies for Genetic Disorders
Seed
Undisclosed
Nov 2020
A2i Therapeutics
Novel Small-molecule Immuno-oncology Agents
Seed
Undisclosed
Oct 2020
Selene Therapeutics
Epilepsy Therapy
Seed
Undisclosed
Sep 2020
Circuit-Bio
Platform of Logical Gene Circuits for Cancer Immunotherapy
Seed
Undisclosed
Aug 2020
ImmPACT Bio
CAR-T Cell Therapies for Treating Cancer
A Round
Undisclosed
May 2020
JAMM Therapeutics
Systemic Lupus Erythematosus Treatment
Seed
Undisclosed
Nov 2019
Protekt Therapeutics
PKR Inhibition for Treating Neurodegenerative Diseases
Undisclosed Round
Undisclosed
Nov 2019
Nevrox
Therapeutic Small Molecule Inhibitor for Treating Neurodegenerative Disorders
Seed
Undisclosed
Jun 2019
MabTrix
Therapeutic Monoclonal Antibody for Bowel Disease
Undisclosed Round
Undisclosed
Jun 2019
ImmPACT Bio
CAR-T Cell Therapies for Treating Cancer
Seed
Undisclosed
May 2019
Pi Therapeutics
Inhibitors for Cancer Treatment
B Round
Undisclosed
Feb 2019
Epeius Pharma
Delivery of Therapeutic Proteins into the Central Nervous System
Seed
Undisclosed
Feb 2019
BiomX
Microbiome Therapies for Chronic Diseases
B Round
Undisclosed
Jan 2019
Moya Bio
Tumor Immune Conditioning Agents
Seed
Undisclosed
Sep 2018
Ramino-Bio
Treatment of Cardiometabolic Diseases Using Enhanced Branched-chain Amino Acids
Seed
Undisclosed
Jun 2017
Mitoconix Bio
Therapeutics for Neurodegenerative Diseases
A Round
Undisclosed
null
TNIK Therapeutics
Small Molecule Inhibitors of TNIK
Undisclosed
null
Bsense Bio Therapeutics
Neuropathic Pain Treatment
Undisclosed
null
HepaRx
Small Molecule Cancer Drugs
Undisclosed
null
Pink Biopharma
Monoclonal Antibody Therapy for Blood and Bone Cancer
Undisclosed
null
Glixogen Therapeutics
Treatment for Enhancing Remyelination in Neurodegenerative Disorders
Undisclosed
null
XL Therapeutics
Treatment of Conditions Caused by Deficiencies in WAS Protein Expression
Undisclosed
Media gallery
(0)Locations
Israel
HaMenofim 11, Herzliya, Israel
Offices Abroad
880 3rd Avenue, New York, NY, USA
Locations
Israel
HaMenofim 11, Herzliya, Israel
Offices Abroad
880 3rd Avenue, New York, NY, USA
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Watchlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,